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Abstract 
The Human Papillomavirus (HPV) is the most common sexually transmitted in-
fection in the United States. Though few of its more than one-hundred strains cause 
the recognized symptoms of genital warts, numerous high-risk HPV strains are highly 
correlated with cervical cancer cases. The symptoms of HPV are gender-specific. Men 
and women exhibit different degrees of infectiousness and varied symptoms of infection 
from HPV. Men rarely exhibit symptoms and are therefore silent carriers of these car-
cinogenic agents. In this investigation, we focus on the epidemiological dynamics of a 
high-risk HPV strain (HPV16) in a heterosexual population. A two-sex model is used 
to highlight the impact of asymptomatic infectious males on the dynamics of cervical 
cancer cases in females. Hence, we concentrate on the possible effects of increased HPV 
detection in males on the spread of HPV16 in a heterosexual population, and on the 
incidence of cervical cancer cases associated with HPV16. 
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1 Introduction 
The Human Papillomavirus, HPV, is the most common sexually transmitted infection 
(STI) in the United States[2]. Over 20 million Americans are currently infected with HPV, 
and about 5.5 million new cases will be diagnosed this year[20]. Alarmingly, 70 percent of 
the population has never heard of the disease, but 50 to 75 percent of all Americans will 
acquire some strain of HPV in their lifetime[2, 7]. Currently, no cure is available for HPV, 
but its symptoms can be treated and often cured[7, 26). 
The diverse HPV family consists of over 100 strains, ranging from those that cause 
common warts and plantar warts on the hands and feet to those that affect the genitals, 
each strain infecting different types of epithelial tissue[3]. The approximately 30 strains 
that do affect the genitals can be further subdivided into two categories: low-risk and high-
risk[7]. Biologically, the differences among the low-risk and high-risk strains lie in their varied 
abilities to integrate their genes into the genome of the host cell. High-risk strains actually 
amalgamate their genetic code with the host's genome, and experimental evidence seems to 
show that low-risk strains do not[18]. Two of the HPV's genes, E6 and E7 act as oncogenes, 
with products that actually interfere with the cellular proteins that control the cell cycle 
and DNA repair1[13]. Viral DNA integration together with other contributing factors such 
as smoking, unbalanced diet, old age, or infection with additional STis are sufficient factors 
for the appearance of cancer caused by HPV[18]. 
Low-risk strains (e.g., HPV6 and HPVll) can cause genital warts and mild dysplasia2 
but have not been found to cause cancer[7, 27]. In contrast, high-risk strains are associated 
with cancer[ll, 13]. They can cause flat, nearly-invisible growths and moderate to severe 
dysplasia that may lead to cancer. HPV-linked cancer cases are associated most often with 
cervical cancer, but the virus has been found in cases of anal, vulval, vaginal, and penile 
cancer[26]. Numerous strains have been found to be carcinogenic3 [11]. However, HPV16 is 
the most prominent carcinogenic strain in the United States and throughout the world[26]. 
The most challenging aspect of diagnosing HPV infection lies in the different degrees of 
infectiousness and the varied symptoms of each individual. Depending on a person's immune 
system, symptoms can appear within a week, after a few months, after a number of years, 
or not at all[5]. The symptoms of HPV (i.e., genital warts and dysplasia) can be treated 
and cured, but for subclinical HPV (asymptomatic HPV infections), no cure has been found 
thus far[27]. Since there is no initial HPV test until there are symptoms, most infected 
individuals are transmitting the virus without knowledge of their infection status. 
1 E6 binds to and induces the degradation of the tumor-suppressing protein p53, and E7 interferes with 
retinoblastoma tumor suppressor protein pRBr(13J. 
2 Abnormal cell growth 
3 HPV16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 69 
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Clinical tests do exist that can inform individuals of their HPV status. The Digene 
Hybrid Capture II test is the only test used commercially[2, 6]. The testing process involves 
taking a tissue sample from the individual and testing the sample for HPV DNA. Currrently, 
the Digene Hybrid Capture II test is only FDA 4-approved for use in women. This test is 
not approved for males because the thick skin of the penis precludes obtaining a good tissue 
sample, and the test yields a large number of false-negatives[6]. An individual can always 
be tested for HPV antibodies, but this test does not prove a person is currently infected or 
infectious, only that they have come into contact with the virus in the past. 
Once a person acquires a strain of HPV, it is in his or her body forever, but in 80 percent of 
HPV cases, the host's immune system is able to suppress the virus within 18 months[7, 18]. 
When the immune system has the virus under control, the individual becomes no longer 
infectious, and their symptoms and infectiousness rarely recur. Once the host immune system 
has suppressed a specific strain, he or she will not be able to be infected with that particular 
strain again. They could be infected with a different strain, or they could acquire more than 
one strain of HPV in one sexual encounter. The latter is referred to as superinfection, which 
occurs in about one-third of HPV cases[7]. 
Few options exist to prevent contraction of genital HPV. As HPV spreads via skin-
to-skin contact, condoms cannot fully prevent a person from transmitting or contracting 
HPV. Hence, abstinence is the only true means of protection from the virus. Being in a 
monagamous sexual relationship also reduces the chances of infection[4]. 
Annual anal, vaginal, and penile exams are important in detecting symptoms that would 
otherwise go unnoticed. In particular, Papanicoloaou smears (Pap smears) are crucial in early 
detection of dysplasia. While the exams do not prevent warts or dysplasia from occurring, 
they can detect them before they progress to more serious health problems such as cervical 
cancer[1]. Exams also allow for diagnosis and subsequent treatment. 
Worldwide, cervical cancer has the second highest mortality among cancers that affect 
women(25, 27]. In 1990, about 360,000 women were diagnosed with cervical cancer and half of 
them lost their lives to the disease[17, 15]. In 2002, over 4,000 of the 13,000 women diagnosed 
with cervical cancer in the U.S. will suffer the same fate[28]. The mortality rate from cervical 
cancer in America has decreased significantly during the past few decades, mostly because of 
early diagnosis and intervention due to the Pap smear, but even in countries where screening 
is often used, cancer remains a serious concern[14]. HPV transmission rates are high, and 
it has been shown that up to 99 percent of all cases of cervical cancer can be attributed to 
HPV infections of high-risk strains[2, 17, 27]. Because HPV16 is found in for approximately 
50 percent of cervical cancer cases, it is this strain that is the focus of our research[17, 21]. 
In the research done by Mandelblatt et al. on the benefits and costs of HPV testing, 
4 Food and Drug Administration 
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it was determined that most lives being lost to cervical cancer could be reclaimed by using 
Pap and HPV tests in women simultaneously[14). Their research did not investigate the 
effects of screening and treating the male population. Men contribute greatly to the spread 
of this disease, as their infectiousness is much greater than that of women. They are silent 
carriers of the carcinogenic agents, and we believe that early detection of HPV in men will 
also decrease the spread of the virus. 
2 Methodology 
2.1 Model Assumptions 
1. We assume homogeneous mixing in our model, implying that all individuals in our 
population have identical sexual behavior and that they randomly choose their sexual 
partners. 
2. We assume that immunity to HPV16, once acquired, is permanent. Few recovered 
individuals experience spontaneous reoccurrence of the virus, where the virus reappears 
many years, usually decades, after it was acquired by the host and suppressed by the 
immune system. This can happen because when the immune system is weakened due 
to smoking, old age, or immuno-deficiency virii[26). The comparatively small number 
of people on who regress into the infectious category after recovery leads us to consider 
this phenomenal insignificant. In addition, the fact that spontaneous reoccurence takes 
place decades after initial infection means that the individual may have already left 
the sexually active population by that time. 
3. Though we include recruitment into and exit from of our sexually active population, 
we assume constant male and female population sizes. This is a good assumption 
for communities with small growth rates and stable age distributions. The dynamics 
of the disease would, therefore, stabilize before the population size changed signifi-
cantly. There may be communities where this assumption must be altered (developing 
countries where the birth rate is very high and where exit from the sexually active 
population is regularly by means of natural death at a young age), but we do not 
examine them in this report. Since deaths due to HPV-related cancer are very small 
as compared to the total number of female deaths in our population (1:500 per year in 
U.S.[8]), we do not include cancer-related deaths in our model. 
4. Chronically infected individuals are assumed to have a different rate of infection than 
those who are initially infected. The model also integrates the fact that men are 
proportionally more infectious than women. 
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5. We use standard incidence as the infection rate. Because we have a constant popu-
lation, analysis of the same model with mass action would have the same dynamics, 
with all instances of {3 in the equations and equilibria being scaled by N-1• We use 
standard incidence because we define {3 N to be the total rate of sufficient infectious 
contacts in the population. Then {3N · ~ · ~ = {31 ~ is the rate of sufficient infectious 
contact between a suseptible and an infectious individual. 
6. The model and its analysis focus on the interaction between the two genders, and 
therefore assumes heterosexual interaction as the only possibility for transmission of 
the disease. We assume that the two genders have equal population sizes. 
7. Our per-individual rate of transmission is assumed to be constant, and a constant 
screening rate is assumed. Although only a certain percentage of the sexually active 
population gets tested regularly, we assume that individuals are randomly and ho-
mogeneously screened(14]. A constant treatment rate of screened individuals with a 
certain proportion of success is assumed for those in the initially infected class. The 
assumption of a constant treatment rate corresponds to the regular frequency of the 
Pap smears, combined with the treatment that is administered whenever abnormal 
cells are found. 
8. We include a constant treatment rate of chronic individuals similar to the screening-
and-treatment for initially infected individuals. Successful treatment imparts strain 
immunity to the treated individual, while unsuccessfully treated individuals remain in 
the chronic class. While it is true that individuals might not be sexually active for a few 
weeks after treatment, the average time spent as a chronically infected individual is so 
large that the short period of abstinence is considered to be insignificant in comparison. 
2.2 Model 
In order to describe HPV transmission, we employ a two-sex model with solely heterosexual 
interaction. In our model, we have reduced important aspects of the disease dynamics to the 
following. First, a person enters the susceptible classes (S) once he or she becomes sexually 
active. If and when interaction occurs with someone from the initially infected (I) or the 
chronically infected (C) classes of the opposite gender, a person becomes infected and goes 
to the intially infected class. Individuals leave the initially infected class at a constant per-
individual rate. As the immune system attempts to clears the virus, a fraction of individuals 
gain permanent immunity (R), while others progress to chronic infection. Individuals are also 
screened at a constant per-individual rate, and for a fraction of these individuals, treatment 
of symptoms is successful and provides permanent immunity to the strain. Once in the 
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chronic state, a person may be able to fight off the disease with the help of treatment after 
screening and successful diagnosis. With four stages for each gender, our SICR model is a 
two-gender, heterosexual system drawn in Figure 1. 
Figure 1: Schematic for the Two-Gender SICR Model 
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The dynamics of our model as represented by the following eight ordinary differential 
equations, the variables and parameters of which are described in Table 1. 
dS,(t) Im Cm (1) 
dt - J-LNf- f318f-- f328f-- J-LSf Nm Nm 
di,(t) Im Cm [J-L ] (2) 
dt - f31Sf Nm + f328f Nm - If + 'Y + (}f 
dC1(t) If[py + Ofqf]- (J.L + "'f )C1 (3) dt -
dR,(t) [(1- Ph+ (1- qf)Of]I, + KfCf- J.LRf (4) dt -
dSm(t) If cf (5) 
dt - J-LNm- /338m Nf- /348m Nf- J-LSm 
dim(t) If Cf (6) dt - /338m Nf +/348m Nf - Im[J-L + 'Y +Om] 
dCm(t) 
Im[py + Omqm] - (J.L + Km)Cm (7) dt -
dRm(t) [(1- Ph+ (1- qm)Om]Im + K.mCm- J-LRm (8) dt -
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TABLE 1: PARAMETER NOTATION AND MEANING 
s, susceptible females 
If initially infected females 
cf chronically infected females 
Rf recovered females 
Nf total female population 
Sm susceptible males 
lm initially infected males 
Cm chronically infected males 
Rm recovered males 
Nm total male population 
'Y natural rate at which individuals leave If, Im 
p proportion of Ib Im with failed immune response 
1-p proportion of Ib Im with successful immune response 
(31 contact rate between Sf and Im 
(32 contact rate between Sf and Cm 
(33 contact rate between Sm and If 
(34 contact rate between Sm and Cf 
()f rate at which females If are screened and subsequently treated 
qf proportion of screened women who do not recover with treatment 
1- Qf proportion of screened women who recover with treatment 
Kf treatment-recovery rate of Cf 
()m rate at which males in Im are screened and subsequently treated 
Qm proportion of screened men who do not recover with treatment 
1-qm proportion of screened men who recover with treatment 
Km treatment-recovery rate of Cm 
3 Expression Analysis 
Heesterbeek defines Ro as the "expected number of secondary cases (new infected individuals) 
produced by one infectious individual during its entire infectious life in a [totally] susceptible 
population . . . "[23]. In the case of our two-sex model, we expect Ro to be the expected 
number of individuals of one gender that one index case in the same gender will cause in 
an entirely susceptible sexually active population. If each infective individual causes more 
than one secondary infection during his infectious life-span (Ro > 1), it is intuitive that 
the epidemic will sustain itself. Likewise, if each infective does not cause more than one 
secondary infection during his infectious life-span (Ro < 1), the number of infectives in 
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the population will tend toward zero, i.e., there is no endemic equilibrium. The~ = 1 
threshold is important in the epidemic model, as determining what happens in the model 
as ~ crosses that threshold can give insight into how the system is affected by changes in 
various parameters. 
3.1 Disease-Free Equilibrium and Ro 
We begin our search for the expression for ~ by looking at the stability of the disease-
free equilibrium (DFE). We expect the disease-free equilibrium to be locally asymptotically 
stable when ~ < 1 and unstable when ~ > 1. By solving for the critical points of the 
differential equations 1-8, we find that 
DFE = (N,, 0, 0, 0, Nm, 0, 0, 0). 
\Ve will use the following two lemmas from [24] and (29] to explore the stability of the 
disease-free equilibrium, first defining the following notation: 
f 00 = limsupf(t). 
t-+oo 
Lemma 3.1 Iff, g : ~+ -+ ~ are bounded, differentiable functions, then 
limsup(J(t) + g(t)) :5 f 00 + g00 , 
t-+oo 
and if limt ..... 00g(t) exists, 
limsup(J(t} + g(t)) = f 00 +lim g(t). 
t-+oo t-+oo 
Lemma 3.2 {Fluctuation Lemma) Iff : ~+ -+ ~ is a bounded, twice differentiable function 
with bounded second derivative, then there exists a sequence { tm} -+ oo such that 
lim f(tm) =lim sup f(t). 
m-+oo t-+oo 
This sequence satisfies 
f'(tm) = 0, as m -+ oo. 
Theorem 3.1 If 
( f3t + /32 1YY + Qm8m) ( f3a + /34 P'Y + qtfJJ) < 1 
JL + 'Y + Om JL + ltm JL + 'Y + Om . JL + 'Y + ()I JL + K I JL + 'Y + ()I ' 
then the disease-free equilibrium is globally asymptotically stable. If~> 1, the disease-free 
equilibrium is unstable. 
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Proof of Theorem 3.1: Let Ro < 1. Choose a sequence tm-+ oo such that 
From lemma 3.1, equation (2), and the fact that since Nm = N1, ~ < 1 and W; < 1, we 
have 
0 :$ {31!~ + f32C~- (p, + 'Y + 81 )Ij. 
Similarly, from equations (3, (6), and (7), we have 
0 < (n+q,B1)Xj- (p,+tt,)Cj, 
0 < !JJij + f34Cj- (p, + 'Y + Bm)I~, 
0 < Urt + qm(Jm)X~ - (p, + Km)C~. 
We can use equations (10) and (12) to determine 
coo I < ( n + q,o,) JOO, P, + Kf I 
coo 
m < ( P'Y + qm()m) JOO, p,+~tm m 
and we use the laws of inequalities, expression (9), and expression (11) to find that 
0 < 
0 < 
f3Il~ + /32 (P'Y + qm(Jm)I~- (p, + 'Y +()I )Ij, 
p,+~tm 
f33lj + /34 (P'Y + qi(J I) Ij - (p, + 'Y + Bm)I~. 
P, + KJ 
Further algebraic manipulation yields the following. 
From inequality (15), 
0 < 
0 < 
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(9) 
(10) 
(11) 
(12) 
(13) 
(14) 
(15) 
(16) 
Adding expressions {16) and (17) we have 
0 < 
0 < 
From our definition of Ro, we can write 
but since 1;: > 0 and ~ - 1 < 0, 
I;:(~- 1) < 0, 
I;: - 0, and 
lm(t) --+ 0, t --+ 00. 
By expression (15) we have that 
I1(t) --+ 0, t--+ oo. 
Furthermore, from inequalities (13) and {14) we have 
Cm(t) --+ 0, t--+ 00, 
C1(t) --+ 0, t --+ oo. 
From equations ( 4) and ( 8) we find that 
so 
Rj < ~(((1-p)l'+(1-qt)B,)Ij+KtCI) =0, 
It: < ~(((1-p)l'+(1-qm)Bm)I:'+KmCm) =0, 
R,(t)--+ 0, t--+ oo, 
Rm(t) --+ 0, t--+ 00. 
Finally, because we have constant population in both gender classes, we know that 
S1(t) = N1 - I1(t) - C1(t) - R1(t) --+ N, t --+ oo, 
Sm(t) = Nm -lm(t)- Cm(t)- Rm(t) --+ N, t--+ 00. 
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Hence, the DFE is globally asymptotically stable when Ro < 1. 
Let Ro > 1. Because we have constant population in both gender classes, we can analyze 
the dynamics of J/l Im, 0 1, Om, R/l and Rm, and we will have determined the dynamics for 
the entire system. The Jacobian of our system evaluated at the DFE is 
-(J.L + 'Y + Bf) f3!!L 0 {3 NJ 0 0 lNm 2-Nm 
f3.lim. -(J.L + ')' + Bm) J3lim 0 0 0 3NJ 4NJ 
J= 'fYY + QJBI 0 -(J.L + K,f) 0 0 0 
0 n+qmBm 0 -(J.L + ~) 0 0 
{1- p)'Y+ (1- q1)81 0 "'J 0 -J.L 0 
0 {1- p)'Y+ {1- Qm)Bm 0 ~ 0 -J.L 
In order to determine the stability of the DFE for Ro > 1, we look at the eigenvalues 
of this matrix. If we find any to be positive, we know that the DFE is not stable. The 
characteristic equation of J is 
y(.A) =(.A+ J.L)2(.A4 + a1.A3 + a2.A2 + a3.A + a4), 
where 
a1 - F+J+T+t, 
a2 - F f + FT + Ft + JT + jt + Tt - /31/33, 
a3 - FJT + Fft + fTt- (f3If33(F +f)+ f3If34G + fJ2f33g), 
a4 - F fTt- (f3If33F f + fJ2f33Fg + f3If34fG + fJ2f34gG), 
T - JL+OJ+'Y, 
t 
- J.L+Bm +-y, 
F 
- JL + "'h 
f 
- JL+~, 
G - n+ qfof, 
g 
- n+qm8m. 
Because .All ..\2 = -JL are two eigenvalues of the Jacobian, from the Routh-Hurwitz 
criteria(10], we know that all the roots of the above quartic will be negative if and only 
if the following inequalities are true: 
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However, when Ro > 1, 
al > 0, 
a3 > 0, 
a4 > 0, 
ala2a3 > 2 2 a3 + a1a4. 
a4 - F/Tt(1- ({Jd + f32g)(f32F + {J4G)) 
FfTt 
- FfTt(1- ~) < 0, 
=> a4 < 0. 
Thus, not all of the eigenvalues of the Jacobian evaluated at the disease-free equilbrium are 
negative, and the DFE is unstable for Ro > 1. 0 
3.2 Interpretation of the Reproductive Number 
In order to better analyze the reproductive number we look at each term with the square 
root. The first expression is the contribution by the male gender. {31, fJ2, {33, {J4 are contact 
rates as described in Table 1. The fraction 1'+-r~Bm is the average amount of time that the 
males spend in the initial infected class. The fraction 1'+~ is the average amount of time 
that the males spend in the chronic class. The fraction r;_t;:;:;: is the proportion of males 
that continue be infected and become part of the chronic class. Due to the symmetry of the 
model, the contribution by the expression by females in the system is similar, and comprises 
of the second half of the expression for Ro . 
3.3 Disease Endemic Equilibrium 
Having now determined the dynamics of the disease-free equilibrium for Ro < 1 and Ro > 1, 
we turn our attention to the endemic equilibria. We solve our original set of differential 
equations for the critical points, and we find one unique en~emic equilibrium (DEE). 
DEE= (Sj, Ij, Cj, Rj, s:n, 1:n, c:n, R;,.), 
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where 
S*f Nf[Ro2(p. +Om+ 'Y){Jl. + Km) + f3t{P. + Km) + fh{Jry + QmOm)] {18) -
Ro2 [132(1ry + QmOm) + f3t(P. + Km) + {p. +Om+ 'Y){P. + Km)], 
S*m Nm[Ro2(p. + o, + 'YHP. + Kf) + f3a(P. + Kf) + f34(1ry + q,o, )] {19) -
Ro2 (/34(1ry + q101) + f3a(P. + x:1) + (p. +of+ 'Y)(p. + x:f )], 
I*f p.Nf(P. + Kf ){Ro
2
- 1) {20) - (p. + Kf )(p. + 'Y + 0/ )Ro2 + f3a(p. + Kj) + f34(yy + Qf0/ ), 
l*m P,Nm(P. + Km){Ro2 - 1) {21) - {p. + Km){p. + 'Y + Om)Ro2 + f3t(P. + Km) + f32(1ry + QmOm), 
c·, p.Nf(lry + qfOf ){Ro2 - 1) {22) - (p. + 'Y + 01 )(p. + Kf )Ro2 + f3a(p. + Kf) + f34(yy + Qf0f ), 
C*m P,Nm(lry + Qm0m)(Ro2 - 1) {23) - {p. + 'Y + Om){p. + Km)Ro2 + f3t{P. + Km) + f32(1ry + QmOm), 
R*f N1h(P. + x:1) + o1(p. + x:1)- p.(n + qfef )](Ro2 - 1) (24) - (p. +of+ 'YHP. + Kf )Ro2 + f3a(P. + Kf) + f34(yy + q/Of ), 
R*m Nm['y(p. + Km) + Om(P. + Km)- p.(lry + Qm0m)]{Ro2 - 1) (25) - {p. +Om+ 'Y){p. + Km)Ro2 + f3I(Jl. + Km) + fJJ(JYy + QmOm),. 
As Ro increases from the Ro = 1 threshold, the endemic equilibrium values for all the I, C, 
and R classes go from being always negative to being always positve, and the endemic values 
for Sm and Sf become less than Nm and Nb respectively. This represents the existence of 
a forward bifurcation, as shown in Figure 2. We are unable to prove local stability for the 
endemic equilibrium, though, as can be seen in section 4, our endemic equilibrium seems to 
be stable. 
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Reproductive N001ber 
Figure 2: A bifurcation diagram showing the appearance of initially infected males (upper curve) and 
initially infected females (lower curve) in the positive domain at Ro = 1. The DFE is unstable for Ro > 1 
and stable for Ro < 1. Other non-susceptible classes appear at the same threshold values but are not shown. 
4 Simulations 
TABLE 2: PARAMETER VALUES FOR SIMULATIONS 
Parameter Value 
N, 93088389a 
Nm 93088389a 
'Y .69b 
p .2b 
!31 2 
!32 1.2 
!33 1.33 
!34 .80 
o, 1c 
q, .1 c 
"'' 
.1 
Om .2 
qm .1 
"'m 0 
"U.S. Census Bureau. 
6HPV Hotline, American Social Health Association. 
c Journal of American Medical Association, 2002. 
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Units 
individuals 
individuals 
time-1 
unit less 
time-1 
time-1 
time-1 
time-1 
time-1 
unitless 
time-1 
time-1 
unit less 
time-1 
The complexity of our endemic equilibrium makes it difficult to analyze its stability. 
However, we were able to use simulations done in Matlab5 to predict stability. Figure 
3 represents a portion of the simulations run. Each simulation was run using the same 
parameter values (see Table 2) but varying initial conditions (see Appendix). By inspecting 
the simulations, we note a definite tendency toward our expected endemic equilibrium values 
in every class. Though this does not prove stability of the DEE, it does suggest that the 
system is strongly attracted to the DEE when Ro > 1. 
5 Discussion 
The main goal of our research was to determine the effects that male screening and treat-
ment have on the dynamics of HPV16 transmission in our population. Figure 4 shows the 
relationship between Ro and the screening and treatment rates of males and females. With 
a fixed female screening and treatment rate ( 01), increasing male screening and treatment 
(Om) lowers Ro. We can conclude that increased male screening and treatment will decrease 
the number of secondary infections caused by an individual. Unfortunately as we further 
examine Figure 4, we see that even with screening and treating males five times a year 
(Om= 5), Ro does not decrease below unity. Therefore, no biologically realistic values of Om 
are large enough to drive the endemic to extinction. If we allow both genders, treatment and 
screening rates to increase, we see that Ro can be driven to a, but Ro is still not driven below 
unity for all biologically feasible 01 and Om values. Though the disease cannot be driven to 
extinction with this approach, since Ro does decrease, the incidence of infection in women 
will also become less frequent with increased treatment. Because the number of deaths per 
year due to cervical cancer is highly correlated to the number of individuals infected, this 
lowering of the reproductive number should reduce the number of cervical cancer deaths per 
year. 
6 Future Work 
In the future, we would like to complete analysis of stability of the DEE for Ro > 1. Our 
method for proving the stability for the DFE when Ro < 1 could be used for other models 
with a chronic state, perhaps to analyze a multiple-strain model of a disease like HPV. 
Using this model to investigate the effects of a preventive vaccine for HPV could be 
informative. The effect of the vaccine could be represented in the model in three different 
ways: 
5MATLAB is a registered trademark of The Math Works, Inc., All Rights Reserved. 
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Figure 3: The dynamics of 500 simulations run with the same parameters and different initial values for 
all classes ((a) 8-classes, (b) !-classes, (c) C-classes, (d) R-classes), demonstrating the tendency toward the 
expected equilibrium values. Black represents the male classes; grey represents the female classes. Note that 
the female recovered class has a greater number of individuals than the male recovered class, but only in 
this class does this relationship occur. This is due to the high infectiousness of males, as well as the lack of 
screening and treatment for the male 1- and C-classes. 
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Figure 4: The reproductive number Ro with respect to Om and (} f, decreasing as both screening and 
treatment rates increase. 
1) A change in the rate at which susceptible individuals are infected 
2) Susceptible individuals moving into the recovered class as they are vaccinated 
3) Modifying the model so susceptible individuals go to a "vaccinated" class from which 
they could become susceptible again if the effects of the vaccine wear off. 
We could also show the effects of a therapeutic vaccine on the general population using 
this model. Instead of preventing an individual from initially contracting the virus, the 
therapeutic vaccines that are currently under development (such as those for HIV) would 
be given to individuals who are already infected in order to reduce their infectiousness to 
others[22]. This would affect the rate at which a vaccinated individual's partners become 
infected and could be analyzed after adding certain changes to our model. 
To better reflect reality, age structure could be incorporated into the model, as people of 
certain ages tend to have different sexual behavior. This, in turn, would lead individuals in 
different age classes to have a greater or lesser effect on the system. 
The model could also be modified to include a "core group" of individuals who are at a 
much higher risk of contracting and transmitting HPV. The changes in the dynamics of the 
population resulting from the treatment of the core group could be analyzed. 
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Appendix - MatLab5 fil~ 
function dx=HPVsim(t,x) 
Y.Sf in system is x(l) 
%If in system is x(2) 
%Cf in system is x(3) 
1~ in system is x(4) 
Y.Sm in system is x(5) 
Y.Im in system is x(6) 
Y.Cm in system is x(7) 
Y.Rm in system is x(8) 
global beta! beta2 beta3 beta4 mu gamma theta! theta2 kappa! kappa2 q1 q2 p N 
dx=[mu*N-x(1).*((beta1*x(6)+beta2*x(7))/(N))-mu.*x(1); 
x(1).*((beta1*x(6)+beta2*x(7))/(N))-(gamma+theta1+mu)*x(2); 
x(2)*(p*gamma+q1*theta1)-(mu+kappa1)*x(3); 
((1-p)*gamma+(1-q1)*theta1)*x(2)+kappa1*x(3)-mu*x(4); 
mu*N-x(5).*((beta3*x(2)+beta4*x(3))/(N))-mu.*x(5); 
x(5).*((beta3*x(2)+beta4*x(3))/(N))-(gamma+theta2+mu)*x(6); 
x(6)*(p*gamma+q2*theta2)-(mu+kappa2)*x(7); 
((1-p)*gamma+(1-q2)*theta2)*x(6)+kappa2*x(7)-mu*x(8)]; 
1.1.1.1.1.1.%1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1. 
function y=plotHPV(tf) 
global beta! beta2 beta3 beta4 mu gamma ql p N theta! theta2 kappa! kappa2 q2 
beta1=2; 
beta2 = 1.2; 
ql = .1; 
q2=0.1; 
kappa! = 0.1000; 
kappa2=0; 
n=93088389; 
N=93088389; 
mu =1/50; 
gamma = 0.6900; 
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theta! =1; 
theta2=.2; 
k=kappa2; 
K=kappa1; 
beta3 =2/3*2; 
beta4 = 2/3*1.2; 
RO=(beta1*mu+beta1*k+beta2*p*gamma+beta2*q2*theta2)*(beta3*mu+beta3*K+beta4*p*gamma+ 
beta4*q1*theta1)/((mu+theta1+gamma)*(mu+theta2+gamma)*(mu+k)*(mu+K)); 
p=.2; 
tspan=[O,tf]; 
for i=1:100 
j=i*130004 
xO=[N-6*j;3*j;2*j;j;N-6*j;2*j;3*j;j]; 
[t,z]=ode45('HPVsim',tspan,x0); 
subplot(221),plot(t,z(:,1),'y') 
subplot(221), xlabel('Times (years)') 
subplot(221), ylabel('Individuals') 
hold on 
subplot(221),plot(t,z(:,5),'b') 
subplot(221),title('(a)') 
subplot(222),plot(t,z(:,2),'y') 
subplot(222), xlabel('Times (years)') 
subplot(222), ylabel('Individuals') 
hold on 
subplot(222),plot(t,z(:,6),'b') 
subplot(222),title('(b)') 
subplot(223),plot(t,z(:,3),'y') 
subplot(223), xlabel('Times (years)') 
subplot(223), ylabel('Individuals') 
hold on 
subplot(223),plot{t,z(:,7),'b') 
subplot{223),title('{c)') 
subplot(224),plot(t,z(:,4),'y') 
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subplot(224), xlabel('Times (years)') 
subplot(224), ylabel('Individuals') 
hold on 
subplot(224),plot(t,z(:,8),'b') 
subplot(224),title('(d)') 
end 
%%%%%%%%%%%%%%Y.Y.%Y.Y.Y.Y.Y.Y.Y. 
function y=plotHPV2(tf) 
global beta1 beta2 beta3 beta4 mu gamma q1 p N theta1 theta2 kappa1 kappa2 q2 
beta1=2; 
beta2 = 1.2; 
q1 = .1; 
q2=0.1; 
kappa1 = 0.1000; 
kappa2=0; 
n=93088389; 
N=93088389; 
mu =1/50; 
gamma = 0.6900; 
theta1 =1; 
theta2=.2; 
k=kappa2; 
K=kappa1; 
beta3 =2/3*2; 
beta4 = 2/3*1.2; 
RO=(beta1*mu+beta1*k+beta2*p*gamma+beta2*q2*theta2)*(beta3*mu+beta3*K+beta4*p*gamma+ 
beta4*q1*theta1)/((mu+theta1+gamma)*(mu+theta2+gamma)*(mu+k)*(mu+K)); 
p=.2; 
tspan=[O,tf]; 
for i=1:100 
j=i*130004 
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[t,z]=ode45('HPVsim',tspan,x0); 
figure(1); 
plot(t,z(:,1),'b'); 
hold on 
figure(2) 
plot(t,z(:,2),'r'); 
hold on 
figure(3) 
plot(t,z(: ,3), 'g'); 
hold on 
figure(4) 
plot ( t, z (: , 4) , 'y') ; 
hold on 
figure(5) 
plot(t,z(:,5),'b'); 
hold on 
figure(6) 
plot(t,z(:,6),'m'); 
hold on 
figure(7) 
plot(t,z(:, 7), 'k'); 
hold on 
figure(8) 
plot(t,z(:,S),'c'); 
hold on 
end 
legend('Sf','lf','Cf','Rf','Sm','Im','Cm','Rm'); 
xlabel('T(In years)'); 
ylabel('I(t)'); 
title('Stability of Endemic Equilibrium'); 
hold on 
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